Sign In
Buy APTO
$1.71
+0 (+0%)
At Close: Jul 25, 2025
Aptose Presents Highlights from ASH and Corporate Update Event
05:30pm, Sunday, 06'th Dec 2020
SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, Decembe
Aptose to Hold Corporate Update Sunday, December 6th
07:30am, Tuesday, 01'st Dec 2020
Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers
2 Biotech Stocks That Could Double Your Money
10:00am, Tuesday, 17'th Nov 2020
Aptose Biosciences and Five Prime Therapeutics both have explosive growth potential.
Aptose Biosciences' (APTO) CEO William Rice on Q3 2020 Results - Earnings Call Transcript
10:52pm, Tuesday, 10'th Nov 2020
Aptose Biosciences' (APTO) CEO William Rice on Q3 2020 Results - Earnings Call Transcript
Aptose Reports Results for the Third Quarter 2020
04:01pm, Tuesday, 10'th Nov 2020
Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level
Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting
10:17am, Wednesday, 04'th Nov 2020
Abstracts Accepted for Presentation Abstracts Accepted for Presentation
Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020
04:01pm, Tuesday, 27'th Oct 2020
SAN DIEGO and TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underl
Aptose Biosciences: Validation Impending For This Targeted Oncology Player
06:08pm, Monday, 24'th Aug 2020
APTO's lead candidate, CG-806, is due for important updates in 4Q2020. CG-806 is a unique molecule attempting to enter a competitive and lucrative space.
Aptose Biosciences to Present at Canaccord Genuity 40th Annual Growth Conference
11:30am, Thursday, 06'th Aug 2020
SAN DIEGO and TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlyi
Aptose Reports Results for the Second Quarter 2020
08:01pm, Tuesday, 04'th Aug 2020
CG-806 Phase 1 a/b Study in B Cell Malignancies Advances to Fifth (750mg) Dose CohortFDA Allows IND for Phase 1 a/b Study of CG-806 in AML to Initiate at 450mg Dose LevelAPTO-253 Phase 1b Study in AML
Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020
08:01pm, Tuesday, 21'st Jul 2020
SAN DIEGO and TORONTO, July 21, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.
Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020
08:01pm, Tuesday, 21'st Jul 2020
SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underl
Why Aptose Biosciences Stock Sank Today
07:31pm, Thursday, 16'th Jul 2020
Shares of Aptose Biosciences (NASDAQ: APTO) were sinking 13.7% lower as of 3:22 p.m. EDT on Thursday. The decline came after the company announced the pricing of a stock offering Wednesday evening.
Aptose Announces Pricing of Public Offering of Common Shares
02:49am, Thursday, 16'th Jul 2020
SAN DIEGO and TORONTO, July 15, 2020 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced.
Aptose Announces Proposed Public Offering of Common Shares
08:01pm, Wednesday, 15'th Jul 2020
SAN DIEGO and TORONTO, July 15, 2020 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that it has commenced an underwritten.
